Study Evaluating Safety and Efficacy of UCART Targeting CS1 in Patients With Relapsed/Refractory Multiple Myeloma (MELANI-01)

NCT04142619 · clinicaltrials.gov ↗
PHASE1
Phase
TERMINATED
Status
11
Enrollment
INDUSTRY
Sponsor class

Stopped The trial was discontinued due to sponsor's decision and not a consequence of any safety concern.

Conditions

Interventions

Sponsor

Cellectis S.A.